Literature DB >> 16119969

When should vaccination be contraindicated in children?

Laura Lane1, Arlene Reynolds, Mary Ramsay.   

Abstract

No child should be denied immunisation without serious consideration given to the consequences. In the past, many contraindications to vaccination were based on theoretical concerns. These concerns often assumed an immunoallergic mechanism for adverse reactions, whereas many such events are often due to other causes. Other contraindications were based on evidence of excess risk, but this risk was not always balanced against the higher risk of disease. Therefore, contraindications often varied between countries and over time. In recent years, the widespread availability of less reactogenic vaccines and the common use of combined preparations have prompted a review of contraindications in many countries. Accumulated experience worldwide has allowed the list of conditions that contraindicate vaccination to be reduced. The international consensus now is that there are very few situations in which a child should not be immunised and the only true contraindication applicable to all vaccines is a history of anaphylaxis to a vaccine component or following a previous dose of the vaccine. Health professionals should feel confident in accepting national recommendations and, if in doubt, should refer children for an expert opinion, rather than deny a child protection against a serious infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16119969     DOI: 10.2165/00002018-200528090-00001

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  52 in total

1.  General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP).

Authors:  William L Atkinson; Larry K Pickering; Benjamin Schwartz; Bruce G Weniger; John K Iskander; John C Watson
Journal:  MMWR Recomm Rep       Date:  2002-02-08

2.  Nature, evolution, and appraisal of adverse events and antibody response associated with the fifth consecutive dose of a five-component acellular pertussis-based combination vaccine.

Authors:  Scott A Halperin; David Scheifele; Elaine Mills; Roland Guasparini; Garry Humphreys; Luis Barreto; Bruce Smith
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

3.  Knowledge of the childhood immunization schedule and of contraindications to vaccinate by private and public providers in Los Angeles.

Authors:  D Wood; N Halfon; M Pereyra; J S Hamlin; M Grabowsky
Journal:  Pediatr Infect Dis J       Date:  1996-02       Impact factor: 2.129

4.  Rate of recurrent collapse after vaccination with whole cell pertussis vaccine: follow up study.

Authors:  P E Vermeer-de Bondt; J Labadie; H C Rümke
Journal:  BMJ       Date:  1998-03-21

5.  DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose.

Authors:  L J Baraff; C L Cody; J D Cherry
Journal:  Pediatrics       Date:  1984-01       Impact factor: 7.124

6.  Neomycin sensitivity and the MMR vaccine.

Authors:  R L Rietschel; R Bernier
Journal:  JAMA       Date:  1981-02-13       Impact factor: 56.272

7.  Thiomersal allergy and vaccination reactions.

Authors:  N H Cox; A Forsyth
Journal:  Contact Dermatitis       Date:  1988-04       Impact factor: 6.600

8.  Physician knowledge of catch-up regimens and contraindications for childhood immunizations.

Authors:  Nicole J Cohen; Diane S Lauderdale; Priya B Shete; John B Seal; Robert S Daum
Journal:  Pediatrics       Date:  2003-05       Impact factor: 7.124

9.  Reactions and antibody responses to reinforcing doses of adsorbed and plain tetanus vaccines.

Authors:  L H Collier; S Polakoff; J Mortimer
Journal:  Lancet       Date:  1979-06-30       Impact factor: 79.321

10.  Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children.

Authors:  C L Cody; L J Baraff; J D Cherry; S M Marcy; C R Manclark
Journal:  Pediatrics       Date:  1981-11       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.